Clinical Trials Browser

Observational × Neoplasms, Second Primary × Plasma cell × Clear all

NCT02741544 2022-06-21

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Cataract, Multiple Myeloma, Neoplasms, Second Primary